Startup entity
Against the same-window beat baseline of 23% negative, this entity's 56% share is more negative. regulation accounts for 6 of the 9 tracked stories, while 2 other categories carry the remainder. That works out to roughly 0.5 stories per week across a 131-day span. The busiest single day carried 2.
Last mentioned: Jun 30, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 34 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Against the same-window beat baseline of 23% negative, this entity's 56% share is more negative. regulation accounts for 6 of the 9 tracked stories, while 2 other categories carry the remainder. That works out to roughly 0.5 stories per week across a 131-day span. The busiest single day carried 2. The 7.3 average consequence score is above the beat benchmark of 6.7 in the same window. They are less corroborated than the beat average, carrying 2.4 original sources each against 2.8 for the same window. Venture Capital Firms is most often covered alongside Biotech Startups, which appears in 2 of these 9 stories. We currently track 9 Startup stories that mention Venture Capital Firms, published between February 20, 2026 and June 30, 2026.
Computed from the 9 stories linked to this entity, with beat comparisons drawn from all 1286 Startup stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Venture Capital Firms. Shared-story counts are live from our verified record — not editorial picks.
Congressional Hearings
House and Senate committees begin drafting specific AI regulatory bills based on the framework.
White House Policy Framework
The administration releases the six-principle framework to Congress for legislative action.
Voluntary Commitments
Major AI labs agree to voluntary safety testing and watermarking standards.
Executive Order 14110
President Biden issues the first major Executive Order on Safe, Secure, and Trustworthy AI.
A survey of 350 Indian startups reveals overwhelming operational strain from digital regulations, with 88% reporting constraints and 72% diverting R&D funds to compliance. The Oxford Economics report projects a 20% decline in startup formation over the next decade, costing 245,000 jobs by 2035. However, principles-based regulation could boost formation by 7% and add 80,000 jobs, offering a path forward.
The White House has delivered a comprehensive AI policy framework to Congress, centered on six guiding principles designed to balance rapid innovation with national security and consumer safety. This move signals a transition from executive-led guidance to a formal legislative push that will fundamentally alter the compliance landscape for AI startups and venture capital due diligence.
The US government has revised its fourth-quarter GDP growth estimate downward to a sluggish 0.7%, signaling a sharp cooling of the economy. This deceleration suggests a tightening of capital deployment and a continued shift toward capital efficiency among growth-stage startups.
The NFIB Small Business Optimism Index remained stagnant in early 2026, reflecting a tug-of-war between improved bottom-line profitability and deteriorating expectations for future sales. While internal efficiencies are driving margins, small business owners remain wary of macroeconomic headwinds including volatile energy costs and labor market pressures.
The U.S. Food and Drug Administration is introducing a performance-based bonus system to reward staffers who complete drug reviews ahead of schedule. This regulatory shift aims to clear backlogs and could significantly shorten the path to market for biotech startups and their venture backers.
The FDA has proposed a groundbreaking regulatory system designed to streamline the approval of customized, 'N-of-1' therapies for ultra-rare diseases. This shift marks a transition from traditional mass-market drug evaluation to a platform-based approach, potentially unlocking significant venture investment in precision medicine.
President Donald Trump has officially raised the United States' global tariff rate to 15%, a sweeping protectionist move. This policy shift is expected to significantly disrupt global supply chains, increase costs for hardware startups, and reshape venture capital allocation toward domestic-first business models.
A wave of postponed and downsized initial public offerings is sweeping through the 2026 market as investors demand more realistic valuations. Heightened market volatility and the lackluster performance of recent market entrants have forced many late-stage startups to reconsider their exit timing.
President Trump’s aggressive use of tariffs as a primary economic lever is creating significant uncertainty for hardware and consumer startups. As the administration moves toward broader trade restrictions, venture capitalists are recalibrating risk models to account for supply chain disruptions and potential inflationary pressures.
Venture Capital Firms is linked from 9 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
